TP53 and neoplasm: Next Generation sequencing of her tumor identified mutations in TP53, IDH2, CDH1, and KIT. O(6)-methylguanine methyltransferase (MGMT) proliferation markers were not done on this particular case. While awaiting insurance authorization for TMZ therapy, she developed visual field deficits in her left eye as well as radiographic progression of her tumor as shown in Figure 8.